1 / 34

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Explore the latest AHA findings on Cholesterol, CV Events, and PCSK9 Inhibitors. Learn about statin intolerance, LDL-C reduction, and CAD progression/regression. Understand FH diagnosis, treatment in all ages, and guidance on PCSK9 Inhibitors usage.

amaya-bradshaw
Télécharger la présentation

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cholesterol, CV Events, and PCSK9 InhibitorsHighlights From the AHA

  2. Goal

  3. Statin Intolerance

  4. Serial IVUS

  5. Effect on CHD Events of Lowering LDL-C

  6. Percent Change in LDL-C During Treatment

  7. Primary Endpoint: PAV

  8. Percent of Patients Showing Regression in PAV

  9. Exploratory Subgroup Baseline LDL-C Less Than 70 mg/dL

  10. Safety

  11. Statin Intolerance

  12. Risk Factors and Workup

  13. Common Drugs

  14. Autoimmune Myopathy

  15. Initial Management of Statin Intolerance

  16. GAUSS-3 Trial

  17. Who Gets the PCSK9 Inhibitor?

  18. Patients With FH and Access to Care

  19. FH Prevalence

  20. FH Is Severely Underdiagnosed

  21. The FH Foundation

  22. Access to PCSK9 Inhibitors

  23. Identification and Diagnosis

  24. Treatment in Children and Young Adults

  25. Guidance for the Use of PCSK9 Inhibitors

  26. Progression and Regression of CAD

  27. Atherosclerosis -- A Disease Process

  28. Percent Change in LDL-C During Treatment

  29. Lower Is Better

  30. Abbreviations

More Related